Abstract: The invention relates to fusion polypeptides comprising the extracellular domain of growth hormone linked either directly or indirectly to a polypeptide wherein the polypeptide is not growth hormone.

Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.

Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.

Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.

Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.

Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.

Abstract: Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents.

Abstract: This disclosure relates to erythropoietin (EPO) fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Abstract: We disclose granulocyte colony stimulating factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said proteins.

Abstract: This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Abstract: The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.

Abstract: The disclosure relates to interferon lambda fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and/or dimers, vectors and transformed cells including such nucleic acid molecules, pharmaceutical compositions including the interferon lambda fusion polypeptides and/or dimers, and methods of treating a disorder in a human subject by administering the polypeptides and/or dimers.

Abstract: We describe a circularly permuted growth hormone polypeptide antagonist; compositions comprising said antagonist and methods to treat conditions that would benefit from administration of said antagonist.

Abstract: The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Abstract: We describe a chimeric protein comprising a growth hormone polypeptide linked to a polypeptide comprising the extracellular binding domain of growth hormone receptor; its use in enhancing the growth and metabolism of non-human animals and homodimers comprising said chimeric protein.

Abstract: Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains.

Abstract: We disclose therapeutic polypeptides comprising at least two domains capable of binding to a cytokine receptor, wherein the domains are connected by a peptide linker, wherein the linker optionally comprises a rigid alpha helical region.

Abstract: The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of said modified growth hormone binding domains.